Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 13Sarcoma, Kaposi 4Sarcoma, Ewing 4Leiomyosarcoma 4Rhabdomyosarcoma 3Osteosarcoma 3Liposarcoma 3Breast Neoplasms 3AIDS-related Kaposi sarcoma 3Sarcoma, Synovial 2Pancreatic Neoplasms 2Histiocytoma, Malignant Fibrous 2Acquired Immunodeficiency Syndrome 2Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neuroblastoma 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Multi-centric Castleman's Disease 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Gliosarcoma 1Glioma 1Glioblastoma 1Desmoid Tumors 1

Interventions

Doxorubicin 9Imatinib Mesylate 6pazopanib 4Ifosfamide 4Radiotherapy 3Gemcitabine 3Docetaxel 3pembrolizumab 2Radiation 2Neoadjuvant Therapy 2Mohs Surgery 2Biopsy 23-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2selinexor 1saracatinib 1sapanisertib 1ribociclib 1peposertib 1liposomal doxorubicin 1indolepropanol phosphate 1envafolimab 1cixutumumab 1brigimadlin 1avelumab 1X-Rays 1Watchful Waiting 1TTI-621 1Sunitinib 1Specimen Handling 1Razoxane 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dermatofibrosarcoma × liposomal doxorubicin × Sarcoma × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡